Denali Therapeutics (DNLI) Receives a Buy from Bank of America Securities
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today. The company’s ...
Denali Therapeutics price target lowered to $28 from $30 at BofA
BofA lowered the firm’s price target on Denali Therapeutics (DNLI) to $28 from $30 and keeps a Buy rating on the shares. The firm updated for ...
Proficio Capital Partners LLC Acquires New Shares in Denali Therapeutics Inc. (NASDAQ:DNLI)
Proficio Capital Partners LLC acquired a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 4th quarter, Holdings Channel reports. The fund acquired 25,210 shares of the ...
Morgan Stanley Begins Coverage on Denali Therapeutics (NASDAQ:DNLI)
Morgan Stanley assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report published on Friday, ...
Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback
Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter syndrome drug.
Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer
Oppenheimer analyst Jay Olson lowered the firm’s price target on Denali Therapeutics (DNLI) to $42 from $50 and keeps an Outperform rating on the shares following quarterly results and after hosting ...
North American Morning Briefing: Trump's Tariffs -2-
2seventy bio Inc (TSVT) is expected to report $-0.20 for 4Q. 908 Devices Inc (MASS) is expected to report $-0.39 for 4Q. ATN International Inc (ATNI) is expected to report $-0.24 for 4Q. Aclaris ...